Acute cellular rejection: Impact of donor-specific antibodies and C4d

Transplantation

Volumn 97, Issue 4, 2014, Pages 433-439

  Willicombe, Michelle ^a   Roufosse, Candice ^b   Brookes, Paul ^b   McLean, Adam G ^a   Galliford, Jack ^a   Cairns, Tom ^a   Cook, Terry H ^c   Taube, David ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Acute cellular rejection; C4d; Donor specific antibodies; Glomerulitis; Mixed rejection

Indexed keywords

ALEMTUZUMAB; ANTIBODY; BASILIXIMAB; COMPLEMENT COMPONENT C4D; CORTICOSTEROID; DACLIZUMAB; DONOR SPECIFIC ANTIBODY; HUMAN IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR BLOCKING AGENT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; UNCLASSIFIED DRUG; ZENAX;

ACUTE GRAFT REJECTION; ADULT; ANTIBODY MEDIATED REJECTION; ARTERITIS; ARTICLE; CONTROLLED STUDY; FEMALE; GLOMERULITIS; GRAFT FAILURE; GRAFT RECIPIENT; HUMAN; HUMAN TISSUE; INCIDENCE; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROGNOSIS; RENAL GRAFT DYSFUNCTION; RETROSPECTIVE STUDY; TRANSPLANT GLOMERULOPATHY;

ADULT; ANTIBODIES; ARTERITIS; BIOPSY; CAPILLARIES; COMPLEMENT C4B; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNITY, HUMORAL; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; ISOANTIBODIES; KIDNEY GLOMERULUS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PEPTIDE FRAGMENTS; PROGNOSIS; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES; T-LYMPHOCYTES; TIME FACTORS; TISSUE DONORS;

EID: 84896724119     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000437431.97108.8f     Document Type: Article

References (26)

1. El-Zoghby ZM, Stegall MD, Lager DL, et al. Identifying specific causes of kidney allograft loss. Am J Transplant 2009; 9: 527
2. Meier-Kriesche HU, Schold JD, Srinivas TR, et al. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004; 4: 378
3. Willicombe M, Roufosse C, Brookes P, et al. Antibody-mediated rejection after alemtuzumab induction: Incidence, risk factors, and predictors of poor outcome. Transplantation 2011; 92: 176
4. Mauiyyedi S, Crespo M, Collins AB, et al. Acute humoral rejection in kidney transplantation: II. Morphology, immunopathology, and pathologic classification. J Am Soc Nephrol 2002; 13: 779
5. Al-Aly Z, Reddivari V, Moiz A, et al. Renal allograft biopsies in the era of C4d staining: The need for change in the Banff classification system. Transpl Int 2008; 21: 268
6. Nickeleit V, Andreoni K. The classification and treatment of antibody-mediated renal allograft injury: Where do we stand? Kidney Int 2007; 71: 7
7. Everly MJ, Everly JJ, Arend LJ, et al. Reducing De novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. Am J Transplant 2009; 9: 1063
8. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: Updates and future directions. Am J Transplant 2008; 8: 753
9. Batal I, Lunz JG, Aggarwal N, et al. A critical appraisal of methods to grade transplant glomerulitis in renal allograft biopsies. Am J Transplant 2010; 10: 2442
10. Magil AB. Infiltrating cell types in transplant glomerulitis: Relationship to peritubular capillary C4d deposition. Am J Kidney Dis 2005; 45: 1084
11. Fahim T, Bohmig GA, Exner M, et al. The cellular lesion of humoral rejection: Predominant recruitment of monocytes to peritubular and glomerular capillaries. Am J Transplant 2007; 7: 385
12. Feucht HE, Schneeberger H, Hillebrand G, et al. Capillary deposition of C4d complement fragment and early renal graft loss. Kidney Int 1993; 43: 1333
13. Nickeleit V, Zeiler M, Gudat F, et al. Detection of the complement degradation product C4d in renal allografts: Diagnostic and therapeutic implications. J Am Soc Nephrol 2002; 13: 242
14. Kayler LK, Kiss L, Sharma V, et al. Acute renal allograft rejection: Diagnostic significance of focal peritubular capillary C4d. Transplantation 2008; 85: 813
15. Nickeleit V, Vamvakas EC, Pascual M, et al. The prognostic significance of specific arterial lesions in acute renal allograft rejection. J Am Soc Nephrol 1998; 9: 1301
16. Haas M, Kraus ES, Samaniego-Picota M, et al. Acute renal allograft rejection with intimal arteritis: Histologic predictors of response to therapy and graft survival. Kidney Int 2002; 61: 1516
17. Mueller TF, Einecke G, Reeve J, et al. Microarray analysis of rejection in human kidney transplants using pathogenesis-based transcript sets. Am J Transplant 2007; 7: 2712
18. Reeve J, Einecke G, Mengel M, et al. Diagnosing rejection in renal transplants: A comparison of molecular- and histopathology-based approaches. Am J Transplant 2009; 9: 1802
19. Famulski KS, Einecke G, Sis B, et al. Defining the canonical form of TcellYmediated rejection in human kidney transplants. Am J Transplant 2010; 10: 810
20. Papadimitriou JC, Drachenberg CB, Munivenkatappa R, et al. Glomerular inflammation in renal allografts biopsies after the first year: Cell types and relationship with antibody-mediated rejection and graft outcome. Transplantation 2010; 90: 1478
21. Magil AB, Tinckam K. Monocytes and peritubular capillary C4d deposition in acute renal allograft rejection. Kidney Int 2003; 63: 1888
22. Einecke G, Sis B, Reeve J, et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant 2009; 9: 2520
23. Sis B, Jhangri GS, Riopel J, et al. A new diagnostic algorithm for antibody-mediated microcirculation inflammation in kidney transplants. Am J Transplant 2012; 12: 1168
24. Zhang PL, Malek SK, Blasick TM, et al. C4d positivity is often associated with acute cellular rejection in renal transplant biopsies following Campath-1H (Alemtuzumab) induction. Ann Clin Lab Sci 2007; 37: 121
25. Zhang PL, Malek SK, Prichard JW, et al. Acute cellular rejection predominated by monocytes is a severe form of rejection in human renal recipients with or without Campath-1H (alemtuzumab) induction therapy. Am J Transplant 2005; 5: 604
26. Chan K, Taube D, Roufosse C, et al. Kidney transplantation with minimized maintenance: Alemtuzumab induction with tacrolimus monotherapyVan open label, randomized trial. Transplantation 2011; 92: 774